Thursday 16 October, 2025
Introduction: Small interfering ribonucleic acid (siRNA) is an emerging class of targeted therapies that aims to regulate the expression of…
Read moreAbstracts
Development of a population pharmacokinetic/pharmacodynamic model of lepodisiran, a small interfering RNA targeting lipoprotein(a), in healthy adults
Thursday 16 October, 2025
Introduction: Lipoprotein(a) (Lp(a)) is a low-density lipoprotein-like particle attached to apolipoprotein(a), and elevated Lp(a) levels are associated with increased risk…
Read morePK and PBPK modeling approaches to describe the lung and systemic exposure after inhalation of AZD4604
Thursday 16 October, 2025
Objectives: AZD4604 is an inhaled JAK1 selective inhibitor being developed for treatment of moderate to severe asthma [1]. AZD4604 is…
Read moreDo tree-based machine learning methods outperform Cox regression for progression-free survival prediction in mobocertinib treated lung cancer patients?
Thursday 16 October, 2025
Objectives: Prediction of survival curves, overall survival (OS) and progression-free survival (PFS), based on pre-trained models could help to refine…
Read moreEvusheld hastens viral clearance in COVID-19 hospitalized patients: a modeling analysis of the randomized DisCoVeRy trial
Thursday 16 October, 2025
Introduction. Antiviral treatments for SARS-CoV-2 have been shown to reduce the risk of hospitalization in outpatients [1,2]. However, the use…
Read moreUsing Simcyp Designer to extend a PBPK-QSP Model of Warfarin to Target Binding
Thursday 16 October, 2025
Objectives: CYP2C9 and VKORC1 variant genotypes are associated with increased sensitivity to warfarin. CYP2C9 mediates the majority of the clearance…
Read moreBeyond the Liver; In Silico Screening for Tissue-Specific Oligonucleotide Delivery Receptors
Thursday 16 October, 2025
Introduction: Oligonucleotide therapeutics represent a promising novel treatment modality that has gained wide traction in the past few years due…
Read moreCharacterization of the hepatic distribution of oligonucleotide therapeutics using a cross-species biologics PBPK model
Thursday 16 October, 2025
Introduction: Oligonucleotide therapeutics represent a promising novel treatment modality that has gained wide traction in the past few years due…
Read moreApplication of Physiologically Based Pharmacokinetic Model to Predict Cobicistat Concentration during Pregnancy
Thursday 16 October, 2025
Objectives: Cobicistat, a potent CYP3A4 inactivator that was developed specifically as a pharmacokinetic enhancer, is given in combinations with antiretrovirals…
Read moreDevelopment of a physiologically-based pharmacokinetic model of enzalutamide, a strong CYP3A4 inducer
Thursday 16 October, 2025
Introduction: Enzalutamide (Xtandi®) is a second-generation androgen receptor inhibitor and is approved in more than 40 countries for treating patients…
Read more